miR-10a作为急性髓系白血病MDM2抑制的治疗靶点与预测生物标志物
该研究探讨miR-10a对p53/Rb网络关键成员的调控及其预测MDM2抑制剂敏感性的价值。在细胞系、原代AML标本及接受MDM2抑制剂联合阿糖胞苷治疗的患者中,miR-10a及其下游靶点的表达可预测MDM2抑制剂敏感性并与疗效相关。抑制miR-10a在体外和体内AML模型中诱导Nutlin-3a与阿糖胞苷的协同作用,机制涉及p53介导的细胞毒性凋亡而非细胞保护性自噬。
要点
- miR-10a及其下游靶点表达可预测AML对MDM2抑制剂的敏感性及临床反应。
- 抑制miR-10a可增强Nutlin-3a与阿糖胞苷在AML模型中的协同疗效。
- 协同机制主要通过p53介导的细胞毒性凋亡、减少细胞保护性自噬实现。
核心结论
- miR-10a可作为识别最可能从阿糖胞苷联合MDM2抑制中获益患者的生物标志物。
- miR-10a同时是提高MDM2抑制剂联合阿糖胞苷疗效的可成药靶点。
研究设计与样本
- 研究使用细胞系、原代AML标本及接受MDM2抑制剂联合阿糖胞苷治疗的患者样本。
- 在体外和体内AML模型中验证miR-10a抑制与Nutlin-3a及阿糖胞苷的联合效应。
主要发现
- miR-10a调控p53/Rb网络多个关键成员,包括MDM4、RB1CC1、TFAP2C及p53本身。
- miR-10a及其下游靶点表达在细胞系和原代AML标本中强烈预测MDM2抑制剂敏感性。
- miR-10a及其下游靶点表达与接受MDM2抑制剂联合阿糖胞苷治疗患者的反应相关。
- 抑制miR-10a在体外和体内AML模型中诱导Nutlin-3a与阿糖胞苷的协同作用。
- 协同作用主要通过p53介导的细胞毒性凋亡、牺牲细胞保护性自噬实现。
临床怎么用
- 可检测miR-10a及其下游靶点表达以筛选可能对阿糖胞苷联合MDM2抑制敏感的患者。
- 联合抑制miR-10a可能作为增强MDM2抑制剂联合阿糖胞苷疗效的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pharmacological inhibition of MDM2/4, which activates the critical tumor suppressor p53, has been gaining increasing interest as a strategy for the treatment of acute myeloid leukemia (AML). While clinical trials of MDM2 inhibitors have shown promise, responses have been confined to largely molecularly undefined patients, indicating that new biomarkers and optimized treatment strategies are needed. We previously reported that the microRNA miR-10a is strongly overexpressed in some AML, and demonstrate here that it modulates several key members of the p53/Rb network, including p53 regulator MDM4, Rb regulator RB1CC1, p21 regulator TFAP2C, and p53 itself. The expression of both miR-10a and its downstream targets were strongly predictive of MDM2 inhibitor sensitivity in cell lines, primary AML specimens, and correlated to response in patients treated with both MDM2 inhibitors and cytarabine. Furthermore, miR-10a inhibition induced synergy between MDM2 inhibitor Nutlin-3a and cytarabine in both in vitro and in vivo AML models. Mechanistically this synergism primarily occurs via the p53-mediated activation of cytotoxic apoptosis at the expense of cytoprotective autophagy. Together these findings demonstrate that miR-10a may be useful as both a biomarker to identify patients most likely to respond to cytarabine+MDM2 inhibition and also a druggable target to increase their efficacy.
引用
- Vu TT, Stölzel F, Wang KW, et al. miR-10a as a therapeutic target and predictive biomarker for MDM2 inhibition in acute myeloid leukemia. Leukemia. 2020. PMID: 33262524. doi:10.1038/s41375-020-01095-z
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。